Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases

Haematologica. 2011 Jul;96(7):1067-71. doi: 10.3324/haematol.2010.039214.

Abstract

Post-transplantation lymphoproliferative disorder (PTLD) with plasmacellular differentiation has been reported as a rare subtype of monomorphic B-cell post-transplant lympho-proliferation with histological and immunophenotypical features of plasmacytoma in the non-transplant population. Here we present clinical, laboratory and histopathological features, treatment and outcome of 8 patients from the German prospective PTLD registry. Clinically, extranodal manifestations were common while osteolytic lesions were rare and none of the patients had bone marrow involvement. Immunohistochemistry showed light chain restriction and expression of CD138 without CD20 expression in all samples. An association with Epstein-Barr virus was found in 3 out of 8 cases. We suggest that the Ann Arbor classification is most useful for this disease entity and report a generally good response to treatment including reduction of immuno-suppression, surgery and irradiation in localized disease and systemic chemotherapy analogous to plasmacell myeloma in advanced disease.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antigens, CD / metabolism
  • B-Lymphocytes / metabolism*
  • B-Lymphocytes / pathology*
  • B-Lymphocytes / virology
  • DNA, Viral / blood
  • Epstein-Barr Virus Infections / complications
  • Epstein-Barr Virus Infections / diagnosis
  • Female
  • Herpesvirus 4, Human / physiology
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Organ Transplantation / adverse effects*
  • Plasmacytoma / complications
  • Plasmacytoma / pathology*
  • Plasmacytoma / therapy*
  • Plasmacytoma / virology
  • Transplantation Conditioning / adverse effects
  • Treatment Outcome
  • Young Adult

Substances

  • Antigens, CD
  • DNA, Viral